Short answer
Lilly (Eli) (LLY) filed an 8-K current report with the SEC on October 29, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results for quarter ended September 30, 2026.
Lilly (Eli) 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results for quarter ended September 30, 2026
- Results announced in Eli Lilly’s October 29, 2026 press release, Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $24.4B, up 39%, led by Mounjaro $10.7B and Zepbound $5.4B
- Volume rose 53%, while realized prices fell 15%, highlighting strong demand but increasing pricing pressure
- Reported EPS $7.22, up 16%, despite $4.57 per-share acquired IPR&D charges tied to business development
- 2026 revenue guidance raised to $91B-$92B, while non-GAAP EPS guidance updated to $35.00-$36.00
- FDA approvals expanded Mounjaro, Onswik, Inluriyo, and Jaypirca commercial opportunities; acquisitions broaden depression and autoimmune pipelines
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Lilly (Eli) 8-K filings
Get the next LLY 8-K as it lands
Follow LLY for push alerts, or ask the research agent what this filing means.